Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.

Jan YJ, Yoon J, Chen JF, Teng PC, Yao N, Cheng S, Lozano A, Chu GCY, Chung H, Lu YT, Chen PJ, Wang JJ, Lee YT, Kim M, Zhu Y, Knudsen BS, Feng FY, Garraway IP, Gao AC, Chung LWK, Freeman MR, You S, Tseng HR, Posadas EM.

Theranostics. 2019 Apr 13;9(10):2812-2826. doi: 10.7150/thno.34485. eCollection 2019.

2.

Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression.

Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, Theodros D, Haffner MC, Lotan T, Huang J, Davicioni E, An SS, Riddle RC, Thorek DLJ, Garraway IP, Fertig EJ, Isaacs JT, Brennen WN, Park BH, Hurley PJ.

Cancer Res. 2019 Jul 15;79(14):3636-3650. doi: 10.1158/0008-5472.CAN-18-2931. Epub 2019 May 23.

PMID:
31123087
3.

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.

Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG.

BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.

4.

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.

Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.

5.

Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate.

Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT.

Oncotarget. 2017 Jul 18;8(29):46710-46727. doi: 10.18632/oncotarget.17362.

6.

Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.

Miller ET, Chamie K, Kwan L, Lewis MS, Knudsen BS, Garraway IP.

Cancer Med. 2017 Jan;6(1):163-172. doi: 10.1002/cam4.981. Epub 2016 Dec 20.

7.

Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone.

Liu S, Cadaneanu RM, Zhang B, Huo L, Lai K, Li X, Galet C, Grogan TR, Elashoff D, Freedland SJ, Rettig M, Aronson WJ, Knudsen BS, Lewis MS, Garraway IP.

PLoS One. 2016 Oct 6;11(10):e0163232. doi: 10.1371/journal.pone.0163232. eCollection 2016.

8.

Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome.

You S, Knudsen BS, Erho N, Alshalalfa M, Takhar M, Al-Deen Ashab H, Davicioni E, Karnes RJ, Klein EA, Den RB, Ross AE, Schaeffer EM, Garraway IP, Kim J, Freeman MR.

Cancer Res. 2016 Sep 1;76(17):4948-58. doi: 10.1158/0008-5472.CAN-16-0902. Epub 2016 Jun 14.

9.

Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Lang JM, Den RB, Garraway IP, Lotan TL, Ross AE, Stoyanova T, Cho SY, Simons JW, Pienta KJ, Soule HR.

Prostate. 2016 Feb;76(2):125-39. doi: 10.1002/pros.23107. Epub 2015 Oct 19. Review.

10.

YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer.

Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B.

Nat Commun. 2015 Sep 1;6:8126. doi: 10.1038/ncomms9126.

11.

Differential gene expression profiling of functionally and developmentally distinct human prostate epithelial populations.

Liu H, Cadaneanu RM, Lai K, Zhang B, Huo L, An DS, Li X, Lewis MS, Garraway IP.

Prostate. 2015 May;75(7):764-76. doi: 10.1002/pros.22959. Epub 2015 Feb 7.

12.

Targeting the RANKL pathway: putting the brakes on prostate cancer progression in bone.

Garraway IP.

J Clin Oncol. 2013 Oct 20;31(30):3838-40. doi: 10.1200/JCO.2013.50.1544. Epub 2013 Sep 16. No abstract available.

PMID:
24043735
13.

Stromal modulation of bladder cancer-initiating cells in a subcutaneous tumor model.

Peek EM, Li DR, Zhang H, Kim HP, Zhang B, Garraway IP, Chin AI.

Am J Cancer Res. 2012;2(6):745-51. Epub 2012 Nov 20.

14.

Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.

Hance MW, Dole K, Gopal U, Bohonowych JE, Jezierska-Drutel A, Neumann CA, Liu H, Garraway IP, Isaacs JS.

J Biol Chem. 2012 Nov 2;287(45):37732-44. doi: 10.1074/jbc.M112.389015. Epub 2012 Sep 18.

15.

Will identification of a prostate cancer stem cell lead to its cure?

Garraway IP.

Urol Oncol. 2012 Jul-Aug;30(4):351-2. No abstract available.

PMID:
22930822
16.

Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells.

Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, Chen D, Li Y, Guo C, Zhang B, Fazli L, Gleave M, Witte ON, Garraway IP, Wu H.

PLoS One. 2012;7(8):e42564. doi: 10.1371/journal.pone.0042564. Epub 2012 Aug 3.

17.

Isolation and characterization of human prostate stem/progenitor cells.

Guo C, Zhang B, Garraway IP.

Methods Mol Biol. 2012;879:315-26. doi: 10.1007/978-1-61779-815-3_18.

PMID:
22610567
18.

Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability.

Guo C, Liu H, Zhang BH, Cadaneanu RM, Mayle AM, Garraway IP.

PLoS One. 2012;7(4):e34219. doi: 10.1371/journal.pone.0034219. Epub 2012 Apr 13.

19.

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, Wu H.

Cancer Cell. 2011 Jun 14;19(6):792-804. doi: 10.1016/j.ccr.2011.05.006. Epub 2011 May 27.

20.

Identification of a cell of origin for human prostate cancer.

Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON.

Science. 2010 Jul 30;329(5991):568-71. doi: 10.1126/science.1189992.

21.

Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo.

Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE, Rubin MA, Witte ON.

Prostate. 2010 Apr 1;70(5):491-501. doi: 10.1002/pros.21083.

22.

Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics.

Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON.

Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20882-7. doi: 10.1073/pnas.0811411106. Epub 2008 Dec 16.

23.

Trefoil factor 3 is overexpressed in human prostate cancer.

Garraway IP, Seligson D, Said J, Horvath S, Reiter RE.

Prostate. 2004 Nov 1;61(3):209-14.

PMID:
15368472
24.

Down-regulation of TDT transcription in CD4(+)CD8(+) thymocytes by Ikaros proteins in direct competition with an Ets activator.

Trinh LA, Ferrini R, Cobb BS, Weinmann AS, Hahm K, Ernst P, Garraway IP, Merkenschlager M, Smale ST.

Genes Dev. 2001 Jul 15;15(14):1817-32.

25.

The initiator element: a paradigm for core promoter heterogeneity within metazoan protein-coding genes.

Smale ST, Jain A, Kaufmann J, Emami KH, Lo K, Garraway IP.

Cold Spring Harb Symp Quant Biol. 1998;63:21-31. Review. No abstract available.

PMID:
10384267
26.

Supplemental Content

Loading ...
Support Center